Viridian Therapeutics Stock Forecast

Stock Price Forecast

According to 17 analysts polled by S&P Global, Viridian Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $36.2. The average 1-year stock price forecast is 45.97% higher than the current stock price, while the lowest is $22 (-11.29%) and the highest is $50 (+101.61%).

Price Target: $36.2 (+45.97%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$22	$36.2	$35	$50
Change	-11.29%	+45.97%	+41.13%	+101.61%

Analyst Ratings

The average analyst rating for Viridian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	13	14	14	14	14	14
Buy	3	3	3	3	3	3
Hold	1	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	17	17	17	17	17	17

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Derek Archila Wells Fargo	Wells Fargo	Buy Reiterates $31	Buy	Reiterates	$31	+25.00%	Oct 14, 2026
Lisa Walter RBC Capital	RBC Capital	Buy Maintains $38	Buy	Maintains	$38	+53.23%	Oct 9, 2026
Rami Katkhuda LifeSci Capital	LifeSci Capital	Buy Maintains $35	Buy	Maintains	$35	+41.13%	Oct 3, 2026
Gregory Renza Truist Financial	Truist Financial	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Sep 1, 2026
Richard Law CFA Goldman Sachs	Goldman Sachs	Buy Maintains $39 → $40	Buy	Maintains	$39 → $40	+61.29%	Aug 20, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

24.30M

from 70.85M

-65.70%

from 70.85M

Revenue Next Year

237.80M

from 24.30M

878.45%

from 24.30M

EPS This Year

-3.92

from -3.32

EPS Next Year

-2.71

from -3.92

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	2.96M	1.77M	314.00K	302.00K	70.85M	24.30M
Revenue Growth	182.19%	-40.20%	-82.28%	-3.82%	23,359.93%	-65.70%
Operating Income	-79.73M	-134.30M	-254.45M	-299.04M	-363.40M	-480.14M
Net Income	-79.41M	-129.87M	-237.73M	-269.95M	-342.60M	-465.62M
EPS	-	-	-	-	-3.32	-3.92
Free Cash Flow	-	-	-	-	-329.51M	-424.80M
No. Analysts	-	-	-	-	-	14

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	45.4M
Avg	24.3M
Low	12.0M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	-35.9%
Avg	-65.7%
Low	-83.0%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-3.41
Avg	-3.92
Low	-4.60

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-